BD (NYSE:BDX) today announced that it has acquired resorbable polymer technology maker Tepha for an undisclosed amount.
Franklin Lakes, N.J.-based BD said that Tepha’s resorbable polymer technology will be used to accelerate BD’s growth of its surgical mesh for soft tissue repair, reconstruction and regeneration. Tepha’s GalaFlex portfolio is also included in the acquisition.
Get the full story on our sister site, MassDevice.
BD (NYSE:BDX) today announced that it has acquired resorbable polymer technology maker Tepha for an undisclosed amount.
Franklin Lakes, N.J.-based BD said that Tepha’s resorbable polymer technology will be used to accelerate BD’s growth of its surgical mesh for soft tissue repair, reconstruction and regeneration. Tepha’s GalaFlex portfolio is also included in the acquisition.
“This strategic acquisition advances BD’s category leadership in surgical mesh and enables future innovations to provide new solutions to physicians and their patients,” Kevin Kelley, worldwide president for BD Surgery, said in a news release. “Tepha’s proprietary polymer is used in BD’s current Phasix Mesh products and is the key technology that enables our products to provide short-term support for soft tissue repairs while enabling rapid tissue ingrowth and reabsorbing into the body over time. The acquisition — including its current …
The foundation nominates devices, biotechnology and pharmaceutical products for its annual Prix Galien awards to highlight products designed to improve the human condition.
“The Awards Committee is excited to introduce the nominees for the 2021 Prix Galien USA Awards. These products have been created by scientists who have dedicated their lives to discovering, developing and distributing life-saving answers for patients,” said Sue Desmond-Hellmann, chair of the Prix Galien USA and Prix Galien International Award committees and former CEO of the Bill & Melinda Gates Foundation.
“We appreciate the opportunity to honor these researchers and their tireless efforts,” Desmond-Hellmann said in a news release.
Nominees need to be FDA-approved for the market within the last five years a…
[Images from BD, Edwards, Alcon and CVRx]
The Galien Foundation today announced the nominees for most innovative medical devices for its 15th annual Prix Galien USA Awards.The foundation nominates devices, biotechnology and pharmaceutical products for its annual Prix Galien awards to highlight products designed to improve the human condition.
“The Awards Committee is excited to introduce the nominees for the 2021 Prix Galien USA Awards. These products have been created by scientists who have dedicated their lives to discovering, developing and distributing life-saving answers for patients,” said Sue Desmond-Hellmann, chair of the Prix Galien USA and Prix Galien International Award committees and former CEO of the Bill & Melinda Gates Foundation.
“We appreciate the opportunity to honor these researchers and their tireless efforts,” Desmond-Hellmann said in a news releas…
BD (NYSE:BDX) announced today that it plans to transform the patient experience through a “One-Stick Hospital Stay” blood collection solution.
Franklin Lakes, N.J.-based BD said in a news release that its recent acquisition of Velano Vascular and its needle-free technology for high-quality blood draws from existing peripheral intravenous catheter (PIVC) lines offers a way to eliminate multiple needlesticks for blood sample collection.
Velano’s FDA-cleared PIVO device paves the way for the “One-Stick Hospital Stay” blood collection and vascular access initiative, providing certain low-acuity patients a chance to have just one “stick” across their entire stay in the hospital.
“As a global leader in vascular access solutions and blood collection, BD has been on the forefront of innovations that improve the patient experience and reduce additional needlesticks,” BD president of medication delivery solut…
The medtech industry’s steady growth provided optimism in recent weeks, but an unforeseen leap sees it hitting new heights now.
MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (July 16) at 145.88 points, a remarkable 27.1% rise week-over-week, registering by far the greatest increase the index has seen since its inception.
Remarkably, the industry’s July 9 tally of 114.79 points a week prior had, at that point, been known to be the index’s all-time best to date. The new high set on Friday of last week totals an increase of 31.09 points.
Medtech’s performance continues to reflect an overall rebound from the struggles brought on by the COVID-19 pandemic, too, especially after this latest unpredictable rise. The industry has registered a 58% increase from the pre-pandemic high of 92.32 (set on Feb. 19, 2020), plus it has fully eclipsed 100% growth from the mid-pand…
BD (NYSE:BDX) announced today that it appointed David F. Melcher and Dr. Claire Pomeroy as directors of its diabetes spinoff.
Franklin Lakes, N.J.-based BD previously announced the separation of its diabetes care business into an independent, publicly traded company called NewCo.
Get the full story at our sister site, Drug Delivery Business News.
BD (NYSE:BDX) today said it has received FDA 510(k) clearance for its PeritX peritoneal catheter system.
Franklin Lakes, N.J.-based BD designed the catheter system to drain symptomatic, recurrent non-malignant ascites, which causes a build-up of fluid in the abdomen.
Get the full story on our sister site, Medical Tubing + Extrusion.
The up-and-down nature of the medtech industry continues to carry through 2021, with a recent dip now followed by a rapid ascent.
MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the week (June 11) at 109.63 points, producing a 2.5% rise from the 106.96-point mark set one week prior (June 4).
It provides a welcome sight after the industry’s progress came to a halt with a -1.4% dip the week before last. The index remains in a position to produce another upswing after demonstrating signs of picking up again when April brought the industry’s all-time best performance.
Even with setbacks that slowed the industry recently, medtech’s performance continues to reflect an overall rebound from the struggles brought on by the COVID-19 pandemic, too. The industry has registered a 18.8% rise from the pre-pandemic high of 92.32 (set on Feb. 19, 2020), plus a 76.5% increase from the mid-pandemic low…
Franklin Lakes, N.J.-based BD’s latest milestone comes less than six months after the company surpassed 1 million orders for vaccine delivery devices in December 2020.
The order total encompasses commitments to governments all over the globe, including the U.S., Australia, Brazil, Canada, France, Germany, India, the Philippines, Saudi Arabia, South Africa, Spain and the UK, among others.
Get the full story at our sister site, Drug Delivery Business News.
BD (NYSE: BDX) is touting that it is the first medical technology company authorized as a Common Vulnerability and Exposures (CVE) Numbering Authority by the CVE Program.
BD officials say the authorization further boosts the company’s healthcare cybersecurity leadership.
Get the full story on our sister site Medical Design & Outsourcing.
BD (NYSE: BDX) is touting that it is the first medical technology company authorized as a Common Vulnerability and Exposures (CVE) Numbering Authority by the CVE Program.
BD officials say the authorization further boosts the company’s healthcare cybersecurity leadership. Cybersecurity has become a major issue for the medical device industry, with FDA even appointing its first medtech cybersecurity chief this year.
“The CVE Program is the de facto international standard for vulnerability identification and naming,” CVE board member Chris Levendis said in a June 2 news release from BD. “Being authorized as a CVE Numbering Authority demonstrates mature vulnerability management practices and a strong commitment to cybersecurity. By making accurate and timely vulnerability information available, CNAs like BD help their customers streamline early-stage vulnerability management.”
BD has developed a mature Coordinated Vulnerability …